SLC6A1-related epilepsy is a genetic epilepsy syndrome caused by heterozygous pathogenic variants in the SLC6A1 gene, which encodes GAT-1 (GABA transporter 1), the principal transporter responsible for reuptake of GABA from the synaptic cleft. Loss of GAT-1 function leads to impaired GABA clearance, desensitization of GABA-A receptors, and network hyperexcitability. The most common phenotype is myoclonic-atonic epilepsy (MAE), also known as Doose syndrome, though the spectrum ranges from childhood absence epilepsy to severe developmental encephalopathy[@slc6a1_2015][@slc6a1_2018].
¶ Genetics and Molecular Basis
SLC6A1 is located on chromosome 3p25.3 and encodes GAT-1, a sodium- and chloride-dependent GABA transporter. GAT-1 is expressed in both neurons and astrocytes and is responsible for:
- Reuptake of synaptic GABA into presynaptic terminals (primary mechanism)
- Astrocytic uptake of GABA for recycling or metabolism
- Regulation of extracellular GABA concentrations
- Prevention of GABA spillover to adjacent synapses
GAT-1 is the dominant GABA transporter in the brain. When GAT-1 function is reduced:
- GABA persists longer in the synaptic cleft
- Initial excessive GABA receptor activation leads to receptor desensitization
- Compensatory downregulation of GABA-A receptor expression may occur
- Net effect: reduced effective inhibition → network hyperexcitability
| Variant Type |
Frequency |
Typical Impact |
| Missense |
~50% |
Reduced transporter function; variable severity |
| Nonsense |
~25% |
Premature truncation; absent protein |
| Frameshift |
~10% |
Loss-of-function; typically severe |
| Splice site |
~10% |
Aberrant mRNA; variable |
| Copy number |
~5% |
Deletions/duplications |
| Metric |
Value |
| Prevalence |
~1:10,000-20,000 for MAE; SLC6A1 accounts for ~1-2% of genetic epilepsies |
| Inheritance |
Autosomal dominant (de novo in ~90% of cases) |
| Sex ratio |
Equal males and females |
| Seizure onset |
1-5 years (MAE); 4-10 years (CAE) |
The most common presentation of SLC6A1 variants:
Seizure types:
- Myoclonic seizures: Sudden, brief jerks of limbs or face; often multiple per day
- Atonic seizures: Sudden loss of muscle tone ("drop attacks"); most disabling feature
- Absence seizures: Typical 3 Hz spike-wave; may be brief
- Tonic-clonic seizures: Generalized convulsive seizures
- Myoclonic-atonic: Combined seizures
Course:
- Onset typically 1-5 years
- Initially may present with febrile seizures or generalized tonic-clonic
- Myoclonic-atonic pattern emerges over months
- Variable response to ASMs
- Cognitive outcome varies: ~40-50% have normal IQ, ~50-60% have ID
A subset of SLC6A1 patients present with pure absence seizures resembling classical CAE:
- Onset 4-10 years
- Typical 3 Hz spike-wave on EEG
- Less severe cognitive outcome
- May remit or persist into adulthood
- Missense variants in transmembrane domains: More likely to cause MAE
- Missense variants in extracellular loops: May cause milder CAE phenotype
- Truncating variants: More likely associated with developmental delay, ID
Features suggesting SLC6A1-related epilepsy:
- Onset 1-5 years with myoclonic/atonic seizures
- Multiple seizure types (myoclonic, atonic, absence, tonic-clonic)
- Generalized EEG patterns (4-6 Hz spike-wave)
- Variable cognitive outcome
- Family history (autosomal dominant)
- Epilepsy gene panel: Tests SLC6A1 along with other MAE genes (SCN1A, CHD2, etc.)
- Whole exome sequencing: Identifies SLC6A1 and other causes
- SLC6A1-targeted analysis: Confirm known family variant
¶ EEG and Neuroimaging
- EEG: Generalized spike-wave (3-6 Hz), photosensitivity common; background normal to mildly abnormal
- MRI: Usually normal; no specific structural findings
SLC6A1 epilepsy is variable in ASM response. Valproic acid is typically first-line:
| Drug |
Evidence |
Notes |
| Valproic acid |
Moderate |
Broad-spectrum; first-line for MAE |
| Ethosuximide |
Moderate |
Effective for absence component; limited for myoclonic/atonic |
| Clobazam |
Low-moderate |
Adjunct; tachyphylaxis common |
| Stiripentol |
Low-moderate |
May help as add-on |
| Levetiracetam |
Low |
Often ineffective |
| Tiagabine |
AVOID |
GAT-1 inhibitor — would worsen condition by further reducing GABA reuptake |
- Ketogenic diet: May help some patients; mechanism may compensate for GABAergic dysfunction
- Vagus nerve stimulation (VNS): Option for refractory cases
SLC6A1 is an excellent gene therapy target:
- Clear monogenic loss-of-function mechanism
- Well-characterized pathophysiology
- Small gene size (~1.8 kb coding) fits easily in AAV
- Preclinical data in Slc6a1 knockout mice support approach
SB-001 (formerly TX-004, developed by Takeda/Shinobi/Recode) is an AAV-based gene therapy delivering functional SLC6A1 (GAT-1) to neurons:
- Delivers wild-type SLC6A1 coding sequence
- Uses neuronal-specific promoter (synapsin)
- Targets neurons to restore GABA reuptake
- Delivered via ICV or intrathecal administration
Preclinical data in Slc6a1 knockout mice showed:
- Partial restoration of GABA uptake activity
- Reduced seizure susceptibility
- Improved behavioral outcomes
See AAV gene therapy hub for more on the SLC6A1 program.
| Outcome |
Details |
| Seizure outcome |
Variable; 20-40% achieve seizure freedom with treatment |
| Cognitive outcome |
40-50% normal IQ; 50-60% mild-moderate ID |
| Long-term |
Many improve with age; some maintain seizures into adulthood |
| SUDEP risk |
Present but lower than Dravet or Lennox-Gastaut |
¶ Research and Open Questions
- GAT-1 compensation — are GAT-2/GAT-3 upregulated in response to GAT-1 loss?
- Therapeutic threshold — what percentage of wild-type GAT-1 levels is sufficient?
- Critical period — when must SLC6A1 function be restored?
- ASM selection — which patients respond best to which medications?
- Biomarkers — what indicates successful GAT-1 restoration (EEG? GABA levels?)?
- [@slc6a1_2015] SLC6A1 myoclonic-atonic epilepsy: clinical and genetic characterization
- [@slc6a1_2018] GAT-1 dysfunction and epilepsy: insights from SLC6A1 variants